Physician profile
Njeri Maina
NPI 1720213838
$43,690.91
in general payments reported to CMS, 2019-2025
39 companies · $17K in 2025
The $17K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $1,874 · 2021: $13K · 2022: $2,128 · 2023: $2,665 · 2024: $5,903 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $7,734 · Consulting Fee: $3,165 · Travel and Lodging: $255 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,115.00 |
| Food and Beverage | $7,734.26 |
| Consulting Fee | $3,165.00 |
| Travel and Lodging | $254.81 |
| Education | $188.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $11,716.00 | 2019-2025 | Haegarda, Hizentra |
| Genzyme Corporation | $8,650.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $8,060.25 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $6,678.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,100.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $916.29 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $802.08 | 2020-2025 | Cuvitru, Takhzyro, Cinryze |
| Genentech USA, INC. | $636.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $517.95 | 2019-2025 | |
| Pfizer INC. | $506.17 | 2019-2025 | |
| Amgen INC. | $377.80 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $306.88 | 2020-2025 | Cutaquig, Panzyga |
| Teva Pharmaceuticals USA, INC. | $297.93 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $297.41 | 2023-2025 | Orladeyo |
| Kaleo, INC. | $282.33 | 2019-2023 | Auvi-Q |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $248.17 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $176.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.31 | 2020-2023 | Ofev |
| Grifols USA, LLC | $163.55 | 2022-2025 | Xembify |
| Pharming Healthcare, INC. | $100.88 | 2019-2025 | Ruconest |
| Leo Pharma INC. | $79.62 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $77.38 | 2024-2025 | Ebglyss |
| Alk-Abello, INC | $74.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $73.59 | 2024 | Voquezna |
| Organon LLC | $66.64 | 2025 | Vtama |
| Ionis Pharmaceuticals, INC. | $61.60 | 2025 | Dawnzera |
| Incyte Corporation | $33.91 | 2021-2022 | |
| Shire North American Group INC | $33.83 | 2019 | |
| Blueprint Medicines Corporation | $32.43 | 2025 | Ayvakit |
| Genentech, INC. | $31.40 | 2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $27.72 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $20.76 | 2023 | |
| Arcutis Biotherapeutics, INC. | $20.47 | 2025 | Zoryve |
| Aytu Biopharma, INC. | $18.59 | 2020 | |
| Mylan Specialty L.P. | $16.82 | 2022 | |
| Uswm, LLC | $16.00 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Njeri Maina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.